A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1

Inclusion Criteria: * Willing to provide written informed consent or assent and to comply with study requirements * Confirmation of PH1 disease * Meet the 24 hour urine oxalate excretion requirements * If taking Vitamin B6 (pyridoxine), must have been on stable regimen for at least 90 days Exclusion Criteria: * Clinically significant health concerns (with the exception of PH1) or clinical evidence of extrarenal systemic oxalosis * Clinically significant abnormal laboratory results * Known active or evidence of HIV or hepatitis B or C infection * An estimated GFR of \< 30 mL/min/1.73m\^2 at screening * Received an investigational agent within 30 days or 5 half-lives before the first dose of study drug or are in follow-up of another clinical study * History of kidney or liver transplant * Known history of multiple drug allergies or allergic reaction to an oligonucleotide or GalNAc * History of intolerance to subcutaneous injection * Women who are pregnant, planning a pregnancy, or breast-feeding or those of child bearing potential and not willing to use contraception * History of alcohol abuse within the last 12 months, or unable or unwilling to limit alcohol consumption throughout the study